hers glp 1 How do GLP-1s work for weight loss? #shorts #shortvideo Hims & Hers Launches New

Finally, the expanded indication landscape suggests that the GLP-1 platform will increasingly compete not just within obesity, but across MASH, cardiovascular protection, and potentially other metabolic conditions

Ongoing and planned trials (Supplementary Table 3

Preclinical studies have identified that GLP-1 analogs such as exendin-4 and GLP-1RAs have direct anti-atherosclerotic and anti-inflammatory effects that may contribute to their cardio- and neuroprotective nature.[42] GLP-1RAs can also directly interact with cardiomyocytes, inducing receptor-mediated ischemic conditioning that decreases myocardial infarct size in test animals receiving GLP-1RAs.[43] Similar effects were noted in rodent brains, with liraglutide reducing cerebral infarct volume in rats.[42] Randomized clinical trials (RCTs) also identified that exenatide similarly reduced myocardial infarct size and liraglutide reduced the resulting necrotic area in human patients following a MI.[43] This may account for the reduced need for coronary revascularization in patients on GLP-1RAs.[12] Despite the findings of overall improvements to composite cardiovascular outcomes, GLP-1RAs showed a non-significant trend toward reducing MI risk and did not affect rates of hospitalization for unstable angina in patients with diabetes.[12] These agents tend to have a stronger effect on stroke reduction in such patients, highlighting the complexity and variability of cardiovascular disease and its sequelae

69: 11351143 [DOI] [PubMed] [Google Scholar] 114.Creutzfeldt W, Ebert R, Willms B, et al

Here is a comprehensive comparison based on clinical trial data

These medications, increasingly prescribed for glycaemic control and weight management, raise important questions for new mothers requiring ongoing metabolic treatment